Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
-
NZ internal report warns of Chinese military forays in Pacific
-
Japan to play Brazil in World Cup knockouts after nervy Sweden draw
-
Dutch march into World Cup knockouts as group winners
-
Better to qualify this way, says Ecuador World Cup hero Plata
-
Ivory Coast see 'no limits' after reaching World Cup knockouts for first time
-
Advocaat 'proud' of Curacao as minnows exit World Cup
-
Germany committed 'tactical suicide', says Nagelsmann
-
Iglesias -- Spanish World Cup striker unafraid to speak out about injustice
-
Quake-hit Venezuela's hospitals care for children left alone
-
Anderson to join Man City from Forest for British record fee: reports
-
Cole grabs PGA Travelers lead with Scheffler one back
-
Ecuador upset Germany to reach World Cup last 32 as Curacao eliminated
-
De Silva century rescues Sri Lanka in first Test
-
Ecuador edge Germany to squeeze into World Cup last 32
-
Pepe steers Ivory Coast into World Cup last 32 as Curacao go home
-
Spain women's star Putellas to join London City Lionesses
-
WNBA suspends Thomas for fist to Clark's throat
-
England showing Premier League edge at World Cup: Eze
-
UK'S King Charles breaks precedent to reveal £30 mn paid in taxes since 2022
-
Nasdaq falls again on mixed day for US stocks, oil prices rise
-
Yoon grabs early Women's PGA Championship lead with Korda in hunt
-
France squad look to do grieving Deschamps proud in final World Cup group game
-
Will Taylor Swift and Travis Kelce wed in New York? Clues abound
-
Mayweather's Athens fight with Zambidis is off: report
-
Lawyer says Vondrousova 'should appeal' against four-year ban
-
Alonso committed to Aston Martin, but keeping options open
-
Hospitals raise alert as heatwave slams Europe
-
Events cancelled, records loom as heatwave reaches Germany
-
'Alligator Alcatraz' detention center shuts in US: official
-
Czech striker Schick ends international career
-
Tennis great Evert says 'relentless' cancer has returned
-
US says wants deal with Iran, but not 'at any price'
-
Colombian president-elect gives armed groups one month to surrender
-
US Supreme Court hands win to Bayer in weedkiller litigation
-
New Zealand's Latham and Conway pile on the runs before Stokes breakthrough
-
Apple raises prices for MacBooks and iPads, as costs soar over AI
-
Dominant Osaka sails into Bad Homburg semis
-
UK suffers as heat breaks new June record
-
US Supreme Court says asylum seekers can be turned away before border
-
Binance to suspend crypto services in several EU countries
-
Olivia Wilde looks at evolving relationships in 'The Invite'
-
Hamilton reveals neck injury that hampered debut year with Ferrari
-
Rows, drones and 'sorry' Son as South Korea await World Cup fate
-
Noosha Aubel and Dietmar Woidke: How Potsdam Is Letting Down a Young Child with Profound Disabilities
-
Antonelli welcomes Mercedes upgrade as Russell says beware Hamilton
-
Greek families receive keepsakes of Holocaust victims
-
Antonelli welcomes Mercedes upgrade ast Russell says beware Hamilton
-
Easyjet rejects latest takeover bid but leaves door ajar
-
HRW denounces Turkey arrests ahead of NATO summit
-
Macron hosts Meloni for Riviera talks after Trump rift
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.
Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft (PDX) models.
"This license marks a significant milestone in our capability to support biopharmaceutical partners in developing next-generation radiotherapeutics," stated Ronnie Morris, CEO of Champions Oncology. "By integrating this expertise with our well-characterized PDX platform, we are uniquely positioned to drive the advancement of radiopharmaceutical development with unparalleled translational precision."
This comprehensive program will support drug developers across a range of modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.
For partnership inquiries or to learn more, please contact us at https://www.championsoncology.com/contact-us.
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Rachel Bunting, MS, MBA
VP, Global Marketing
[email protected]
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
Ch.Campbell--AT
